Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson's Disease with Dementia Patients

Next Previous
Trial Profile

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson's Disease with Dementia Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blarcamesine (Primary)
  • Indications Dementia; Parkinson's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Anavex Life Sciences

    • Most Recent Events

    • 09 May 2023 Interim results published in an Anavex Life Sciences Media Release.
    • 04 Aug 2022 Results of Whole blood transcriptomics analysis identifying treatment impact on compensatory pathways by restoring key neurodegenerative pathways functionality, including Alzheimers disease pathway, presented at the Alzheimer's Association International Conference 2022
    • 31 Jul 2022 Results presented in the Anavex Life Sciences Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top